| P2093 | author name string | M H Chen | |
| | K Cheng | |
| | J R Tata | |
| | G Hickey | |
| | B Butler | |
| | W W Chan | |
| | R P Nargund | |
| | A A Patchett | |
| | D B Johnston | |
| | K J Barakat | |
| P2860 | cites work | Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men | Q30437028 |
| | Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects | Q30465795 |
| | Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. | Q34337041 |
| | Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin | Q35615472 |
| | Conformational energy studies and in vitro and in vivo activity data on growth hormone-releasing peptides | Q36604718 |
| | Molecular conformation and biological activity of central nervous system active drugs | Q40088896 |
| | Untoward Events in Patients Treated with Growth Hormone in the USA | Q41135234 |
| | Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone | Q41193598 |
| | Novel tetracyclic spiropiperidines. 3. 1-arylspiro[indoline-3,4'-piperidine]s as potential antidepressants | Q42252684 |
| | Evidence for a Role of Protein Kinase-C in His-D-Trp Ala-Trp-D-Phe-Lys-NH2-Induced Growth Hormone Release from Rat Primary Pituitary Cells | Q42463561 |
| | The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture | Q42492988 |
| | A nonpeptidyl growth hormone secretagogue | Q42558239 |
| | Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel non-peptidyl GH secretagogue | Q48272725 |
| | Spiropiperidines as high-affinity, selective .sigma. ligands | Q48479003 |
| | On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone | Q48673475 |
| | Central actions of peptide and non-peptide growth hormone secretagogues in the rat | Q59649487 |
| | Orally active, nonpeptide oxytocin antagonists | Q67506389 |
| | Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists | Q69843588 |
| | Detection of hormone release from individual cells in mixed populations using a reverse hemolytic plaque assay | Q70424784 |
| | Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6 | Q72166028 |
| | Design, Synthesis, and Biological Activity of Peptides which Release Growth Hormone in Vitro* | Q72449346 |
| | Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue, in beagles | Q72753189 |
| | Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin) | Q72792442 |
| | On a peptidomimetic growth hormone-releasing peptide | Q72810060 |
| | GH releasing peptides--structure and kinetics | Q72929119 |
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 7001-7005 | |
| P577 | publication date | 1995-07-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue | |
| P478 | volume | 92 | |